Locations:
Search IconSearch

1-Minute Consult: Can Calcium and Vitamin D Supplementation Adequately Treat Most Patients With Osteoporosis?

Metabolic bone disease expert weighs evidence

17-RHE-1177 Deal_ConsultQD_Hero Image_650x450pxl

Editor’s note: This article originally appeared in the Cleveland Clinic Journal of Medicine.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

By Chad Deal, MD

In short, no. Although calcium and vitamin D play an important role, they are not sufficient when used alone. Rather, they should be used in combination with an antiresportive agent such as estrogen, raloxifene, alendronate, risedronate or calcitonin.

Categories of Bone Loss

The World Health Organization has defined three levels of low bone mass; the definitions are based on T scores, which are standard deviation units below peak bone mass:

  • Osteopenia—a T score between -1 and -2.5.
  • Osteoporosis—a T score less than -2.5.
  • Severe osteoporosis—a T score less than -2.5 with a fracture.

The National Osteoporosis Foundation recommends treatment with an antiresorptive agent in patients with a T score less than -2.0; patients with T scores less than -1.5 to -2.0 should also be treated if they have any of the following risk factors: family history of osteoporosis; previous fracture; current tobacco use; body weight less than 127 pounds. Many other factors such as steroid use are also important and houls be considered.

Studies of calcium and vitamin D

In almost all randomized controlled trials of antiresorptive agents, the control groups took calcium and vitamin D supplements. In these trials, patients who took alendronate, risedronate or raloxifene had significantly fewer fractures than those who took calcium and vitamin D alone. Thus, we conclude that supplements alone are not adequate.

Still, calcium and vitamin D are important in treating age-related bone loss, as they reduce the rate of bone loss and possibly reduce fracture risk.

Advertisement

To read the full in-depth answer to this question by Chad Deal, MD, Head of the Center for Osteoporosis and Metabolic Bone Disease, including an overview of studies of calcium and vitamin D, visit Cleveland Clinic Journal of Medicine. Dr. Deal reviews the use of biologics to treat metabolic bone disease here.

Advertisement

Related Articles

Red rash on legs
Case: Symptoms Atypical for This Disease on the Rise

High fevers, diffuse rashes pointed to an unexpected diagnosis

CAR T cell illustration
December 30, 2025/Rheumatology & Immunology
Summit Focuses on Clinical and Research Advances in Biologic Therapies

No-cost learning and CME credit are part of this webcast series

vasculitis rash
There’s No Debating the Value of Vasculitis Summit on Webcast

Summit broadens understanding of new therapies and disease management

Older man looking at phone
December 2, 2025/Rheumatology & Immunology
Lifestyle eCoaching Shows Promise for PsA-Related Mental Health Needs

Program empowers users with PsA to take charge of their mental well being

Blue and red balls symbolizing nitric oxide
Nitrogen: The Usung Hero of Vascular Physiology

Nitric oxide plays a key role in vascular physiology

Dr. Littlejohn with patient in clinic
Lupus Case Underscores CAR T-Cell Potential for Quality-of-Life Benefit

CAR T-cell therapy may offer reason for optimism that those with SLE can experience improvement in quality of life.

Drs. Elaine Husni and Shashank Cheemalavagu in the lab
A Novel Mechanism in Psoriatic Disease Pathogenesis

Unraveling the TNFA receptor 2/dendritic cell axis

scan images of auditory canal and sacroiliac joints
Case: Unusual Disease Patterns, Vague Symptoms, Striking Imaging

Nasal bridge inflammation, ear swelling and neck stiffness narrow the differential diagnosis

Ad